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The taxanes paclitaxel and docetaxel are potent chemotherapeutic agents that block tubulin depolymerisation, leading to the
inhibition of microtubule dynamics and cell cycle arrest. Although docetaxel and paclitaxel share a mutual tubulin binding site,
mechanistic and pharmacological differences exist between these agents. For example, docetaxel has increased potency and an
improved therapeutic index compared with paclitaxel, and its short 1-h infusion offers a substantial clinical advantage over the
prolonged infusion durations required with paclitaxel. In clinical studies, docetaxel monotherapy demonstrated good response rates
and an acceptable toxicity profile in both paclitaxel- and platinum-refractory ovarian cancer patients. In particular, neurotoxicity — a
dominant side effect with both paclitaxel and cisplatin — occurs at a low incidence with docetaxel, making docetaxel a promising
agent for combining cisplatin and other platinum compounds. In Phase II studies, the combination of docetaxel with either cisplatin or
carboplatin has yielded impressive response rates of 69–74 and 81–87%, respectively. Furthermore, Phase III data suggest that
docetaxel–carboplatin and paclitaxel–carboplatin are similarly efficacious with respect to progression-free survival and clinical
response, although neurotoxicity occurs more frequently with the paclitaxel regimen. While paclitaxel–carboplatin remains the
standard treatment for the management of advanced ovarian cancer, docetaxel–carboplatin appears to be a promising alternative,
particularly in terms of minimising the incidence and severity of peripheral neuropathy.
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Ovarian cancer accounts for nearly 4% of cancers among women
and is the leading cause of gynaecological cancer death in the USA
(American Cancer Society, 2003). Indeed, the American Cancer
Society estimates that during 2003 a total of 25400 new cases of
ovarian cancer will be diagnosed in the USA, and that almost
14300 US women will die from this disease (American Cancer
Society, 2003). Platinum-based chemotherapy has been the
cornerstone of therapy for advanced ovarian carcinomas since
the activity — in the early 1980s — of cisplatin-based regimens in
ovarian cancer was first reported (Decker et al, 1982; Lambert and
Berry, 1985; Kaye, 2000). Subsequently, platinum-based combina-
tion therapies have been shown to achieve higher clinical response
rates and longer progression-free intervals than alkylating agents
alone, or nonplatinum regimens, although the evidence for overall
survival benefit with such regimens — in cases of advanced ovarian
cancer — is less compelling (Aabo et al, 1998). More recently, two
large randomised trials, one conducted by the Gynecologic
Oncology Group (GOG) and the other by the European Organisa-
tion for Research and Treatment of Cancer (EORTC), have shown
that administration of the taxane paclitaxel in combination with
cisplatin significantly improves the duration of progression-free
survival and overall survival in women with advanced epithelial
ovarian cancer compared with cisplatin–cyclophosphamide ther-
apy (McGuire et al, 1996; Piccart et al, 2000). Paclitaxel–platinum
combinations are therefore replacing platinum-alkylating agent
regimens as standard first-line therapy in advanced ovarian cancer
(Kaye, 2000). However, since both paclitaxel and cisplatin are
neurotoxic, such combinations are associated with a high degree of
neuropathy. Two recently published large randomised trials have
shown that paclitaxel–carboplatin achieved comparable efficacy
and less toxicity compared with paclitaxel–cisplatin (du Bois et al,
2003; Ozols et al, 2003). It would therefore appear that paclitaxel–
carboplatin may provide another first-line chemotherapy regimen
for the treatment of advanced ovarian cancer.
Docetaxel is a newer member of the taxoid family, derived by a
semisynthetic process from the needles of the European Yew tree
Taxus baccata (Denis et al, 1990). This agent has shown significant
activity in a variety of cancers including breast, lung, ovarian, head
and neck, and gastric cancers. Like paclitaxel, docetaxel acts as a
spindle poison, promoting microtubulin assembly and stabilising
the polymers against depolymerisation, leading to the inhibition of
microtubule dynamics and cell cycle arrest (Ringel and Horwitz,
1991). Although docetaxel and paclitaxel share a mutual tubulin
binding site, mechanistic and pharmacological differences exist.
For example, preclinical studies have shown that — compared
with paclitaxel — docetaxel is a stronger promoter of tubulin
polymerisation in vitro, has a longer intracellular half-life and
demonstrates greater activity in some tumour models (Barasoain
et al, 1991; Ringel and Horwitz, 1991; Bissery et al, 1995).
Docetaxel has demonstrated potent in vitro and in vivo cytotoxic
activity against a range of tumour types, particularly ovarian
cancer. Indeed, docetaxel was found to be 1.2–2.6 times more
cytotoxic than paclitaxel and over 1000 times more cytotoxic than
cisplatin or etoposide in ovarian carcinoma cell lines (Kelland and
Abel, 1992; Engblom et al, 1997). Docetaxel has also been shown to
act synergistically with cisplatin and carboplatin in epithelial
ovarian cancer in vitro, and to have potent cytotoxic activity in *Correspondence: Dr N Katsumata; E-mail: nkatsuma@ncc.go.jp
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Abel, 1992). Furthermore, there is incomplete cross-resistance
between paclitaxel and docetaxel in a range of in vitro human
tumour cell lines (including ovarian) (Hanauske et al, 1992); and
in clinical trials, docetaxel 75 or 100mgm
 2 every 3 weeks has
been found to be an active second-line agent in patients refractory
to paclitaxel-based regimens (Verschraegen et al, 2000).
Docetaxel and paclitaxel also have substantially different toxicity
profiles. Of particular note, docetaxel is associated with only
minimal neurotoxicity, which has prompted interest in the use of
this agent as an alternative to paclitaxel for inclusion in platinum-
based regimens for the management of advanced ovarian cancer
(Markman et al, 2001; Vasey on behalf of the Scottish Gynaeco-
logical Cancer Trials Group, 2002). In the light of these
observations, this paper examines clinical experience to date with
docetaxel and discusses the potential of this drug as an alternative
to paclitaxel in the management of ovarian cancer.
DOCETAXEL MONOTHERAPY
Phase I trials
The clinical efficacy of docetaxel was first reported in Phase I
studies in patients with a range of solid tumours (including
ovarian cancer) resistant to standard chemotherapy in use at the
time of these early trials (Cortes and Pazdur, 1995). These studies
identified a short 1-h infusion as the optimal means of delivering
docetaxel (Aapro et al, 1992; Bissett et al, 1993; Extra et al, 1993;
Cortes and Pazdur, 1995) — offering a substantial clinical
advantage over paclitaxel, which requires longer infusion times
(3 or 24h). Neutropenia was the major toxicity reported with
docetaxel in Phase I trials; this was dose- but not schedule-
dependent (Cortes and Pazdur, 1995). Other side effects included
mucositis, hypersensitivity reactions, asthenia and fluid retention,
although fluid retention is now routinely prevented by the
prophylactic administration of steroids (Cortes and Pazdur,
1995; Kaye et al, 1997; Piccart et al, 1997).
Phase II trials
The safety and efficacy of docetaxel 100mgm
 2 administered
every 3 weeks as a 1-h intravenous infusion have been evaluated in
four Phase II trials in women with platinum-refractory advanced
ovarian cancer. Two of these studies were multicentre European
trials conducted by the Early Clinical Trials Group (ECTG) and the
Clinical Screening Group (CSG) of the EORTC, and two were
single-centre trials conducted in the USA by the MD Anderson
Cancer Center (MDACC) and the Memorial Sloan–Kettering
Cancer Center (MSKCC) (Aapro et al, 1994; Francis et al, 1994;
Piccart et al, 1995; Kavanagh et al, 1996). A total of 340 patients
were included, all of whom had been previously treated with
cisplatin or carboplatin and had recurrent or progressive disease.
A summary of the characteristics of the patients enrolled in these
trials and their response to docetaxel therapy are provided in
Table 1.
Overall response rates across the four individual trials ranged
from 26 to 40% (Kaye et al, 1997). When response data from the
four trials were pooled, there were 14 complete responses and 79
partial responses among the 315 evaluable patients, giving an
overall response rate of 30% (95% confidence intervals (CI): 19–
36%) (Kaye et al, 1997). Importantly, docetaxel maintained this
high response rate even in the most platinum-refractory patients,
with an overall response rate of 28% (95% CI: 19–36%) in the 155
patients with a treatment-free interval of less than 4 months. The
median duration of response and the median survival in the four
individual trials ranged from 4.5 to 6.7 months and from 8 to 10.4
months, respectively. The overall response rates obtained with
docetaxel in these four Phase II studies compare favourably with
the 22% response rate reported with paclitaxel in a large
population-based study in women with platinum-refractory
disease (Trimble et al, 1993).
The toxicity profile of docetaxel was similar across the four trials
and reflected observations made in the Phase I studies. Neutro-
penia was the most frequently reported grade III–IV toxicity (90–
96% of patients) and was followed by severe fluid retention, which
was experienced by 8–12% of patients. However, none of these
studies included steroid prophylaxis, which has since been shown
to reduce significantly the incidence and severity of fluid retention,
and also the frequency of treatment discontinuation due to this
adverse event. Consequently, routine premedication with a steroid
(e.g. dexamethasone) has been incorporated in subsequent
docetaxel studies. Other grade III–IV toxicities reported in the
four Phase II trials in advanced ovarian cancer included acute
hypersensitivity (7–10% of patients), diarrhoea (6–10%),
Table 1 Efficacy of docetaxel 100mgm
 2 every 3 weeks in women with recurrent or progressive ovarian cancer previously treated with platinum
compounds: results from four Phase II studies (adapted from Kaye et al, 1997)
Study
ECTG CSG MDACC MSKCC
Patient characteristics
No. of patients
Treated 132 124 59 25
Evaluable for efficacy 116 121 55 23
Median age [range] (years) 54 [30–75] 57 [35–76] 58 [26–70] 59 [36–73]
Interval since prior platinum therapy (% of patients)
0–4 months 30 38 100 83
4–12 months 35 62 — 17
412 months 35 — — —
Response to therapy (evaluable population)
Response rates (% of patients)
Complete response 3 7 5 0
Partial response 25 19 35 35
No change 41 36 38 43
Median response duration [range] (months) 6.7 [4.1–17.4] 5.8 [1.4–13.5] 4.5 [1–12] 5.0 [3–9]
Median survival (months) 8.4 10.4 10 8
CSG¼Clinical Screening Group; ECTG¼Early Clinical Trials Group; MDACC¼MD Anderson Cancer Center; MSKCC¼Memorial Sloan–Kettering Cancer Center.
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studies, it can be concluded that docetaxel demonstrates
significant clinical activity against advanced ovarian cancer and
has a different spectrum of toxicity to paclitaxel, which is
commonly associated with neuropathy and myalgia.
Phase II trials using low-dose docetaxel
As an alternative to administering prophylactic steroids to reduce
the degree of fluid retention, Japanese studies have tended to use
lower doses of docetaxel than those used in European and
American trials. In a Phase I study conducted in Japan in patients
with solid tumours, the maximum tolerated dose of docetaxel
without premedication ranged between 70 and 90mgm
 2 (Taguchi
et al, 1994). On this basis, the Japanese Phase II programme for
docetaxel was initiated at a dose of 60mgm
 2. However, while this
dose generated good response rates in women with breast cancer,
results in ovarian cancer were disappointing (only one partial
response and no complete responses in 36 evaluable patients)
(Noda et al, 1994). In a subsequent Phase II pilot study, the dose of
docetaxel was increased to 70mgm
 2 every 3 weeks in Japanese
women with platinum-pretreated advanced ovarian cancer. This
resulted in an acceptable tolerability profile and delivered a
response rate of 24% in the 25 evaluable patients (Fujiwara et al,
1999).
The clinical efficacy and tolerability of docetaxel 70mgm
 2
every 3 weeks in advanced ovarian cancer have since been
confirmed in a larger Phase II study in Japan (Katsumata et al,
2000). Here, 60 women previously treated with platinum-based
therapies received a median of four courses of docetaxel, 98% of
which were given without the need for dose reduction. Response
was achieved in 25% of platinum-refractory patients (within 0–6
months of the platinum-free interval) and 33% of platinum-
sensitive patients (within 6 and more months of the platinum-free
interval); the overall response rate was 28% for all patients
combined. Haematological effects were the main toxicities
associated with therapy and were recorded at frequencies similar
to those observed in European and US Phase II programmes.
However, nonhaematological toxicities tended to be milder than
had been reported with higher docetaxel dosages. In particular,
there was a low incidence of severe hypersensitivity reactions or
fluid retention, despite the fact that steroid prophylaxis was not
given in this or any other Japanese Phase II trial. Given that the
response rates achieved in this trial were similar to those achieved
in the higher-dose European and US trials, reducing the docetaxel
dosage to 70mgm
 2 may be the preferred chemotherapeutic
approach in patients for whom steroid premedication is inap-
propriate.
DOCETAXEL–PLATINUM: AN ALTERNATIVE
FIRST-LINE THERAPY
Overview of docetaxel–cisplatin trials
As mentioned previously, the superiority of paclitaxel–cisplatin
regimens as first-line chemotherapy over cisplatin–cyclopho-
sphamide therapy (the previous standard of care) has been
established in two large randomised trials in women with advanced
epithelial ovarian cancer (McGuire et al, 1996; Piccart et al, 2000).
One of the major limitations of this combination is that both
paclitaxel and cisplatin are neurotoxic, and co-administration of
these two agents can result in a high incidence of peripheral
neuropathy. This has led several groups, including the French
Group d’Investigateurs Nationaux pour l’Etude des Cancers
Ovariens (GINECO), the Russian RAMS group and the Scottish
Gynaecological Clinical Trials Group (SGCTG), to evaluate the
potential of docetaxel as an alternative taxoid to paclitaxel for use
in combination with cisplatin in this patient population (Guastalla
et al, 1999; Vasey et al, 1999; Gorbounova et al, 2000). In each of
these studies, docetaxel 75mgm
 2 and cisplatin 75mgm
 2 were
administered every 3 weeks for six courses with routine steroid
premedication.
In an interim analysis of the Russian RAMS study, the overall
rate of clinical response to docetaxel–cisplatin among the 38
evaluable patients was 73.6%, of which 42.1% were complete
responses and 31.5% partial responses (Gorbounova et al, 2000);
four patients experienced a pathological complete response. In the
GINECO trial, docetaxel–cisplatin was associated with a patholo-
gical complete response in 21% of the 43 evaluable patients, and a
disease-free survival of 16 months after a median 16 months
follow-up (Guastalla et al, 1999). In both trials, docetaxel–cisplatin
had an acceptable tolerability profile. No unexpected toxicities
were reported (neutropenia was the most common adverse event)
and the rates of neurological toxicity and fluid retention were low.
The SGCTG trial differed from the RAMS and GINECO studies
in that patients were divided into two treatment cohorts: one
receiving cisplatin 75mgm
 2 plus docetaxel 75mgm
 2 (n¼49),
the other receiving cisplatin 75mgm
 2 plus docetaxel 85mgm
 2
(n¼51) (Vasey et al, 1999). In addition, the study was designed
primarily to assess the toxicity of the docetaxel–cisplatin
combination, its primary end point being the proportion of
patients who discontinued therapy because of fluid retention. Only
two-thirds of patients completed the full six courses of therapy,
with half of all patient withdrawals being attributed to treatment-
related toxicity. However, no patients withdrew because of fluid
retention and only 14 patients (14%) developed peripheral oedema
requiring diuretics, which confirmed previous reports that
premedication with a 5-day course of corticosteroids reduces the
severity of this adverse event. The incidence of moderate to severe
peripheral neuropathy was low (6% grade III). Among the 39
patients who were available for assessment of clinical response
after three or six cycles of chemotherapy, 38% had a complete
response and 31% a partial response.
Overview of docetaxel–carboplatin trials
There is now a large body of evidence to suggest that in patients
with ovarian cancer, carboplatin provides comparable antitumour
activity to cisplatin, but with significantly less toxicity when given
as monotherapy or in combination with other agents (Aabo et al,
1998). The addition of carboplatin to a taxane regimen was
expected to result in less emesis and neurotoxicity than cisplatin–
taxane therapy, although concerns were expressed that the
combined myelotoxicity of carboplatin and a taxane might result
in significant myelosuppression, necessitating dose reduction.
However, experience with paclitaxel–carboplatin has shown that
the two agents can be given safely without reduction in the dosage
of either component (Kaye, 2000; du Bois et al, 2003). Indeed, it
appears that carboplatin-associated thrombocytopenia is reduced
by co-administration of paclitaxel — an effect thought to occur at
the level of the megakaryocyte rather than by a general
pharmacokinetic interaction (Kaye, 2000). Given these promising
results, a series of Phase I/II trials have been conducted to assess
docetaxel–carboplatin regimens in this setting, and Phase III trials
are underway.
Phase I/II experience
In a recent Phase I trial of docetaxel and carboplatin as first-line
therapy, 22 patients with ovarian cancer were given docetaxel as a
1-h infusion immediately followed by a 1-h infusion of carboplatin
(Hatae et al, 2002). Dose-limiting toxicities of febrile neutropenia
and grade IV diarrhoea were seen at the dose level of docetaxel
75mgm
 2 and carboplatin AUC 6. Pharmacokinetic data for
docetaxel were similar to those reported for docetaxel adminis-
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interactions were seen. The recommended doses were determined
as docetaxel 75mgm
 2 plus carboplatin AUC 5 or docetaxel
70mgm
 2 plus carboplatin AUC 6.
The efficacy and safety of docetaxel–carboplatin regimens as
first-line therapy for epithelial ovarian cancer were first reported
by the SGCTG group (Vasey et al, 2001). Their feasibility study
included 139 eligible patients (median age 56 years; 79% FIGO
stage III/IV at presentation) treated at one of five docetaxel–
cisplatin dosage levels, with docetaxel doses ranging between 60
and 85mgm
 2, and carboplatin doses ranging between an area
under the concentration–time curve (AUC) of 5 and 7mgml
 1.
Treatment was administered every 3 weeks for six planned cycles,
with a 3-day prophylactic dexamethasone regimen. The overall
clinical/radiological response rate was 66, and 75% of patients had
a CA125 response. Median progression-free survival was 16.6
months at a median follow-up of 19 months. Response to therapy
at each of the five dosage levels is shown in Figure 1. The incidence
of neurotoxicity was extremely low and no patients were removed
from the study as a direct result of this side effect. Indeed, grade II/
III sensory neurotoxicity was reported by fewer than 6% of
patients and there were no cases of motor neuropathy of severity
greater than grade I; these rates of neuropathy are substantially
lower than those reported with paclitaxel–carboplatin regimens. A
summary of the neuropathic toxicities reported at the various
dosage levels is provided in Figure 2. As anticipated, neutropenia
was the major dose-limiting toxicity. CTC grade IV neutropenia
occurred in 75% of patients; however, in only 4% of patients was
this effect associated with sepsis, and prophylactic antibiotics or
growth factors were not routinely required. Grade IV thrombocy-
topenia was seen in only 4.2% of patients and there were no cases
of thrombocytopenic haemorrhage, which suggests that the
platelet-sparing effect of paclitaxel when given with carboplatin
also extends to docetaxel and is therefore most probably a class
effect of the taxoids. On the basis of these results, the dosage
regimens recommended by the SGCTG for further trials were
docetaxel 75mgm
 2 plus carboplatin AUC 5 or 6.
The activity and safety of docetaxel 70–75mgm
 2 plus
carboplatin to AUC 5–6 every 3 weeks in women with stage III–
IV ovarian cancer have been confirmed in three other Phase II
studies involving a total of 66 women, 50 of whom were
chemonaı ¨ve and 16 of whom had received prior platinum-based
therapy (Table 2) (Meyer et al, 1999; Kolevska et al, 2001; Vorobiof
et al, 2001). In these studies, 27–52% of patients achieved a
complete response and 29–53% a partial response following
docetaxel–carboplatin therapy, with overall response rates ranging
from 81 to 87% (Table 2) (Meyer et al, 1999; Kolevska et al, 2001;
Vorobiof et al, 2001). These response rates suggest that this
docetaxel–carboplatin regimen is at least as effective as docetax-
el–cisplatin regimens.
In all of the studies, neutropenia was the major toxicity.
Neurotoxicity was reported in two of the three studies, but the
incidence was very low: Kolevska et al (2001) reported grade I
neuropathy in seven out of 19 patients, whereas Meyer et al (1999)
reported grade II neuropathy in two out of 26 patients and grade I
neuropathy in 15 out of 26 patients (no cases of grade III or
above). Survival and quality of life data have been reported for one
of the three studies — Kolevska and colleagues found that first-line
therapy with docetaxel 70mgm
 2 plus carboplatin to AUC 6 every
21 days was associated with a median progression-free survival of
13.1 months in women with cancer of the ovaries, fallopian tube or
peritoneum (at the time of the report, median overall survival had
not been reached: 9.2þ months) (Kolevska et al, 2001). Over the
course of the study, 50% of patients experienced a 10-point
improvement in the Functional Living Index: Cancer (FLIC)
quality of life questionnaire, with 25% experiencing no change and
25% experiencing a 10-point deterioration in FLIC score (Kolevska
et al, 2001).
Markman et al (2001) have reported similarly high response
rates in a Phase II study employing a lower 60mgm
 2 dose of
docetaxel (Table 2). A total of 50 women with cancer of the ovary
and fallopian tube and primary cancer of the peritoneum were
treated with docetaxel 60mgm
 2 plus carboplatin AUC 6 every 3
weeks for six cycles. The vast majority of patients were chemonaı ¨ve
(94%) and had stage III–IV disease (88%). Of the 42 patients
evaluable for efficacy, 34 (81%) demonstrated objective evidence of
a response, with similar response rates being noted in patients with
ovarian cancer and those with primary peritoneal cancer. At the
time of publication, median progression-free survival had not been
reached, but was greater than 16 months. Grade IV neutropenia
was the most common toxicity (occurring in 64% of patients) and
neuropathy was reported by only three patients (grade I¼1; grade
II¼2). Hypersensitivity reactions were relatively common (34%)
but did not result in the discontinuation of therapy.
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 2 plus carboplatin (C) AUC 5–6 every 3 weeks in women with recurrent or progressive ovarian cancer (OC): results from four Phase II studies
(Meyer et al, 1999; Kolevska et al, 2001; Markman et al, 2001; Vorobiof et al, 2001)
No. of patients evaluable for
Patient
characteristics at
presentation
Response rate (% of evaluable patients)
Length of
follow-up,
median
[range]
Progression-
free survival,
median
[range]
Toxicity (no. of
patients) Reference Regimen Safety Efficacy CR PR Overall
Markman et al (2001) D
60mgm
 2+C
AUC 6 every
21 days for 6
cycles
50 42 Chemotherapy-naı ¨ve
(94%) and platinum-
pretreated (6%)
patients with OC (12%
stage I–II; 88% stage
III–IV)
NS NS 81 21+ months
[12+ to 41+]
416 months Grade IV neutropenia
(32); neutropenic fever
(8); grade III
thrombocytopenia (2);
hypersensitivity (17);
peripheral neuropathy
(3)
Kolevska et al (2001) D
70mgm
 2+C
AUC 6 every
21 days for 6
cycles
19 15 Chemotherapy-naı ¨ve
patients with
suboptimally debulked
stage IIIc (63%) or IV
(37%) OC
27 53 87
a 8.9 months
[0.6–26.4]
13.1 months Grade III/IV toxicities:
b
neutropenia (15);
febrile neutropenia (2);
nausea (2); vomiting
(1); anaemia (2);
thrombocytopenia (3)
oedema (1); weight loss
(1); dehydration (1);
DVT (3); diarrhoea (2)
Meyer et al (1999) D
75mgm
 2+C
AUC 5every 21
days for 6
cycles
27 27 Chemotherapy-naı ¨ve
(41%) and platinum-
pretreated (59%)
patients with stage III–
IV OC
52 29 81 NS NS Neutropenia (grade II/
III, 24);
thrombocytopenia
(grade II/III, 7);
neuropathy (grade II, 2)
Vorobiof et al (2001) D
75mgm
 2+C
AUC 6every 21
days for 6
cycles
20 11
c Chemotherapy-naı ¨ve
patients with stage III–
IV OC
46 36 82 NS NS Grade III–IV toxicities
included anaemia,
leucopenia,
neutropenia,
thrombocytopenia,
nausea and vomiting
aIncludes one minor response.
bData presented as number of episodes.
cIncludes patients with measurable disease and excludes those only evaluable for CA125 response.
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The efficacy and toxicity profile of docetaxel–carboplatin has been
directly compared with that of paclitaxel–carboplatin as first-line
therapy for stage Ic–IV epithelial ovarian cancer in an interna-
tional Phase III randomised trial conducted by the SGCTG. The
trial, named SCOTROC (Scottish Randomised Trial in Ovarian
Cancer), enrolled 1077 chemonaı ¨ve patients between October 1998
and May 2000 from 83 centres in 10 countries. Patients were
treated with carboplatin to AUC 5 plus either docetaxel 75mgm
 2
infused over 1h or paclitaxel 175mgm
 2 infused over 3h. Survival
and longer-term toxicity results were presented at ASCO 2002
(Vasey on behalf of the Scottish Gynaecological Cancer Trials
Group, 2002). These results demonstrate that while the paclitaxel
and docetaxel regimens are of similar efficacy, there are significant
toxicity differences between the two therapies. The median
reported follow-up in surviving patients was 21 months, with
94% followed up for more than 1 year. Docetaxel–carboplatin
achieved similar median progression-free survival to paclitaxel–
carboplatin (15.1 vs 15.4 months) and clinical response rates (66 vs
62%), but the duration of follow-up is currently insufficient to
allow survival comparisons. Nevertheless, paclitaxel–carboplatin
was associated with a significantly higher rate of grade II/III
sensory neuropathy than docetaxel–carboplatin (30 vs 11%; Po
0.01), while docetaxel–carboplatin resulted in a significantly
higher incidence of grade III/IV neutropenia (94 vs 82%;
Po0.001) and febrile neutropenia (10 vs 2%; Po0.001), although
these events were predictable and easily managed (Vasey on behalf
of the Scottish Gynaecological Cancer Trials Group, 2002). Global
quality of life parameters based on the EORTC QLQ-C30
instrument were comparable in both arms. However, using the
ovarian-specific module OV-028 (Cull et al, 2001), patients
reported significantly less severe symptoms of neurotoxicity
(using a score based on tingling in hands or feet and numbness
in fingers or toes) with docetaxel–carboplatin than with paclitax-
el–carboplatin during treatment and also 6 months after
randomisation (both Po0.001).
SUMMARY
Over the last few years, the combination of a platinum compound
such as cisplatin or carboplatin with paclitaxel has emerged as
standard chemotherapy for advanced ovarian cancer (Kaye, 2000).
Notwithstanding the clinical and survival benefits afforded by
these new regimens compared with previous therapies, mortality
from advanced ovarian cancer is high. Thus, research into new
agents and new combinations continues apace with the objective of
improving overall survival and reducing treatment-related toxicity.
Docetaxel offers an alternative taxoid treatment to paclitaxel for
use in this setting. Indeed, there is preclinical evidence that
docetaxel has greater antitumour potency and a better therapeutic
index than paclitaxel (Bissery et al, 1995), and its short 1-h
infusion also offers a substantial clinical advantage over the 3- or
24-h infusion times required for paclitaxel. In clinical studies,
docetaxel monotherapy has demonstrated good response rates and
an acceptable toxicity profile in both paclitaxel- and platinum-
refractory ovarian cancer patients (Kavanagh et al, 1996; Kaye et al,
1997; Verschraegen et al, 2000). Of particular note, neurotoxicity
(a dominant side effect with both paclitaxel and cisplatin) is
infrequent and mild with docetaxel, which implies that this drug is
a promising new taxane for use in combination with cisplatin and
other platinum compounds.
The incorporation of docetaxel into first-line platinum-contain-
ing regimens for advanced ovarian cancer has produced successful
results. In Phase II studies, overall response rates of 69–74% were
achieved with docetaxel 75mgm
 2 plus cisplatin 75mgm
 2;
corresponding rates with docetaxel 75mgm
 2 and carboplatin to
AUC 5–6 were 81–87%. The docetaxel–carboplatin combination
proved to be better tolerated than the docetaxel–cisplatin
combination (Vasey et al, 1999, 2001). A Phase III trial comparing
docetaxel–carboplatin with paclitaxel–carboplatin suggests that
the two taxane regimens are equally efficacious, but demonstrate
clear toxicity differences (Vasey on behalf of the Scottish
Gynaecological Cancer Trials Group, 2002). In particular, paclitax-
el–carboplatin produced significantly more neurotoxicity, leading
to early treatment discontinuation compared with docetaxel–
carboplatin. While paclitaxel–carboplatin is currently the standard
chemotherapy in the clinical setting, docetaxel–carboplatin is an
impressive alternative. It appears that certain patient groups – for
example, patients at high risk of developing treatment-related
neurotoxicity – may benefit from receiving docetaxel as an
alternative to paclitaxel in platinum-based regimens (Markman
et al, 2001; Vasey on behalf of the Scottish Gynaecological Cancer
Trials Group, 2002).
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